VOYAGER MOVES FORWARD WITH ALZHEIMER'S TRIAL

A A

Enrollment in ALADDIN VP-AD-301, the first Phase III clinical trial investigating the safety and efficacy of VP4896 in the treatment of mild to moderate Alzheimer disease, has passed its midpoint ahead of schedule, Voyager Pharmaceutical has announced.

Voyager initiated enrollment in September 2005 and expects to complete enrollment of all 555 subjects before December 31, 2006.

Patients being recruited into the study are 60 years of age or older with mild-to-moderate Alzheimer disease and have been taking Aricept, Exelon, Razadyne (formerly Reminyl) or Cognex for at least four months.